MRTX

Mirati Therapeutics, Inc. Common Stock
MRTX

Overview Fund Activity
Delisted

MRTX was delisted on the 22nd of January, 2024.

Back to rankings

213 hedge funds and large institutions have $3.53B invested in Mirati Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 94 increasing their positions, 50 reducing their positions, and 38 closing their positions.

Holders
213
Holders Change
+6
Holders Change %
+2.9%
% of All Funds
3.4%
Holding in Top 10
9
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+28.57%
% of All Funds
0.14%
New
46
Increased
94
Reduced
50
Closed
38
Calls
$75.7M
Puts
$23.3M
Net Calls
+$52.4M
Net Calls Change
+$30.1M

Top Buyers

1
EC
1
EcoR1 Capital
California
$250M
2
RI
2
RTW Investments
New York
$295M
3
Fidelity Investments
3
Fidelity Investments
Massachusetts
$66.6M
4
BC
4
Boxer Capital
California
$139M
5
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$51.2M

Top Sellers

1
AC
1
Armistice Capital
New York
$59.4M
2
PA
2
Perceptive Advisors
New York
$0
3
Millennium Management
3
Millennium Management
New York
$1.5M
4
Marshall Wace
4
Marshall Wace
United Kingdom
$6.41M
5
Morgan Stanley
5
Morgan Stanley
New York
$107M
Name Market Value Shares Shares
Change 		Shares
Change %
RI
1
RTW Investments
New York
$295M 6,768,514 +2,295,529 +51%
ACA
2
Avoro Capital Advisors
New York
$290M 6,666,666 +1,111,111 +20%
EC
3
EcoR1 Capital
California
$250M 5,748,399 +5,748,399 New
Vanguard Group
4
Vanguard Group
Pennsylvania
$248M 5,699,632 +721,357 +14%
BlackRock
5
BlackRock
New York
$154M 3,544,311 +226,292 +7%
Wellington Management Group
6
Wellington Management Group
Massachusetts
$145M 3,319,922 -68,443 -2%
BC
7
Boxer Capital
California
$139M 3,201,440 +1,201,440 +60%
AH
8
Aviva Holdings
Bahamas
$137M 3,135,966 – –
State Street
9
State Street
Massachusetts
$120M 2,745,968 +164,229 +6%
Morgan Stanley
10
Morgan Stanley
New York
$107M 2,462,132 -382,340 -13%
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$106M 2,433,029 +655,450 +37%
AG
12
Artal Group
Luxembourg
$88.2M 2,024,226 -30,955 -2%
O
13
OrbiMed
New York
$85.3M 1,959,050 +1,045,400 +114%
Assenagon Asset Management
14
Assenagon Asset Management
Luxembourg
$79.5M 1,825,678 +1,016,858 +126%
PBA
15
Paradigm Biocapital Advisors
New York
$72.7M 1,668,116 +224,354 +16%
Fidelity Investments
16
Fidelity Investments
Massachusetts
$66.6M 1,527,828 +1,404,045 +1,134%
CCM
17
Camber Capital Management
Massachusetts
$65.3M 1,500,000 -300,000 -17%
BBA
18
Baker Bros. Advisors
New York
$61.4M 1,409,784 – –
AC
19
Armistice Capital
New York
$59.4M 1,364,098 -2,613,902 -66%
Adage Capital Partners
20
Adage Capital Partners
Massachusetts
$51.2M 1,175,000 +1,175,000 New
Citadel Advisors
21
Citadel Advisors
Florida
$49.3M 1,131,438 +649,620 +135%
RSCM
22
Rock Springs Capital Management
Maryland
$49.3M 1,131,207 +9,560 +0.9%
Fiera Capital (Canada)
23
Fiera Capital (Canada)
Quebec, Canada
$45.3M 1,038,836 +346,803 +50%
FCM
24
Farallon Capital Management
California
$43.6M 1,001,000 +1,001,000 New
CS
25
Candriam SCA
Luxembourg
$38.9M 893,763 +20,000 +2%
1
2 3 4 5